Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 481-486

  Undas, Anetta ^a,b   Nowakowski, Tomasz ^a   Cieśla Dul, Mariola ^b   Sadowski, Jerzy ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Fibrin clot; Fibrinolysis; Inflammation; PAD; Thromboangiitis obliterans

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BLOOD VESSEL PERMEABILITY; BUERGER DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; TURBIDIMETRY;

ADULT; AGED; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; THROMBOANGIITIS OBLITERANS; THROMBOSIS; TREATMENT OUTCOME;

EID: 79953038563     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.040     Document Type: Article

References (33)

1. Aslam F., Haque A., Foody J., Lee L.V. Peripheral arterial disease: current perspectives and new trends in management. South Med J 2009, 102:1141-1149.
2. McDermott M.M., Kerwin D.R., Liu K., et al. Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general practice. J Gen Intern Med 2001, 16:384-390.
3. McDermott M.M., Greenland P., Liu K., et al. The ankle brachial index as a measure of leg functioning and physical activity in peripheral arterial disease: the Walking And Leg Claudication Study. Ann Intern Med 2002, 136:873-883.
4. Merino J., Planos A., Elosua R., et al. Incidence and risk factors of peripheral arterial occlusive disease in a prospective cohort of 700 adult elderly men followed for 5 years. World J Surg 2010, 34:1975-1979.
5. Diehm C., Kareem S., Lawall H. Epidemiology of peripheral arterial disease. Vasa 2004, 33:183-189.
6. Olin J.W. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000, 343:864-869.
7. Aziz M., Boutouyrie P., Bura-Riviere A., et al. Thromboangiitis obliterans and endothelial function. Eur J Clin Invest 2010, 40:518-526.
8. Unlu Y., Karapolat S., Karaca Y., Kiziltunc A. Comparison of levels of inflammatory markers and hemostatic factors in the patients with and without peripheral arterial disease. Thromb Res 2006, 117:357-364.
9. Tzoulaki I., Murray G.D., Price J.F., et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol 2006, 63:334-341.
10. Bennett P.C., Silverman S.H., Gill P.S., Lip G.Y. Peripheral arterial disease and Virchow's triad. Thromb Haemost 2009, 101:1032-1040.
11. Rao A.K., Vaidyula V.R., Bagga S., et al. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2006, 96:738-743.
12. Cooke J.P., Wilson A.M. Biomarkers of peripheral arterial disease. J Am Coll Cardiol 2010, 55:2017-2033.
13. Bini A., Fenoglio J., Mesa-Tejada E., Kudryk B., Kaplan K. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Atherosclerosis 1989, 69:1038-1045.
14. Scott E.M., Ariëns R.A.S., Grant P.J. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004, 24:1558-1566.
15. Undas A., Szuldrzynski K., Stepien E., et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2007, 196:551-558.
16. Fatah K., Hamsten A., Blombäck B., Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992, 68:130-135.
17. Collet J.P., Allali Y., Lesty C., et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006, 26:2567-2573.
18. Ajjan R.A., Standeven K.F., Khanbhai M., et al. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 2009, 29:712-717.
19. Undas A., Podolec P., Zawilska K., et al. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischemic stroke. Stroke 2009, 40:1499-1501.
20. Undas A., Zawilska K., Ciesla-Dul M., et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009, 114:4272-4278.
21. Bhasin N., Parry D.J., Scott D.J., et al. Regarding " Altered fibrin clot structure and function in individuals with intermittent claudication" J Vasc Surg 2009, 49:1088-1089.
22. Papa M.Z., Rabi I., Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg 1996, 11:335-339.
23. Glowacki R., Bald E. Fully automated method for simultaneous determination of total cysteine, cysteinylglycine, glutathione and homocysteine in plasma by HPLC with UV absorbance detection. J Chromatogr B: Anal Technol Biomed Life Sci 2009, 877:3400-3404.
24. Tangelder M.J.D., van Hattum E.S. Antithrombotic therapy in peripheral artery disease-antiplatelet therapy, anticoagulants, both or none. Thromb Haemost 2010, 104:196-199.
25. Carter A.M., Cymbalista C.M., Spector T.D., Grant P.J. Heritability of clot formation, morphology, and lysis. The EuroCLOT Study. Arterioscler Thromb Vasc Biol 2007, 27:2783-2789.
26. Blombäck B., Carlsson K., Hessel B., et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989, 997:96-110.
27. Undas A., Topor-Madry R., Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4mmol/l. Pol Arch Med Wewn 2009, 119:354-359.
28. Undas A., Brozek J., Jankowski M., et al. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006, 26:1397-1404.
29. Wolberg A.S. Thrombin generation and fibrin clot structure. Blood Rev 2007, 21:131-142.
30. Weisel J.W., Litvinov R.I. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 2008, 6:161-180.
31. Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Med Chem 2008, 6:161-180.
32. Standeven K.F., Uitte de Willige S., Carter A.M., Grant P.J. Heritability of clot formation. Semin Thromb Haemost 2009, 35:458-467.
33. Bhasin N., Ariëns R.A., West R.M., et al. Altered fibrin clot architecture and function in the healthy first-degree relatives of subjects with intermittent claudication. J Vasc Surg 2008, 48:1497-1503.